
ArteraAI Prostate wins De Novo nod, expands to mHSPC
On June 4, 2026, Artera said its multimodal AI platform now reaches metastatic hormone‑sensitive prostate cancer, offering individual risk estimates to guide treatment decisions. The company also reports De Novo marketing authorization from the US Food and Drug Administration for ArteraAI Prostate, its risk‑stratification tool for patients with nonmetastatic disease, bringing AI-driven precision to a […]







